You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NSCLC, EGFR, Bim, mutation abundance

Showing 1 - 25 of 6,765
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-small-cell Lung Cancer Trial in Shanghai (gefitinib combined with chemo, gefitinib combined with apatinib, gefitinib single

Unknown status
  • Non-small-cell Lung Cancer
  • gefitinib combined with chemotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital;
Jul 31, 2020

NSCLC Trial in Shanghai (IN10018, Furmonertinib)

Recruiting
  • NSCLC
  • Shanghai, China
    Shanghai Pulmonary Hospital
Aug 8, 2023

Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • EGFR Positive Non-small Cell Lung Cancer
  • Toripalimab plus Chemotherapy
  • (no location specified)
Jul 28, 2023

Non-Small-Cell Lung Cancer Trial in Guangzhou (PLB1004)

Recruiting
  • Non-Small-Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong General Hospital
Aug 25, 2023

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591, Osimertinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
Jul 9, 2023

Central Nervous System Metastatic EGFR Mutation Positive NSCLC

Not yet recruiting
  • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 6, 2023

    Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

    Not yet recruiting
    • Aumolertinib
    • +4 more
    • (no location specified)
    Mar 8, 2023

    Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC

    Completed
    • Non-small Cell Lung Cancer
    • (no location specified)
    May 8, 2023

    NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

    Recruiting
    • NSCLC
    • EGFR Gene Mutation
    • neo-antigen vaccine
    • Nanjing, China
      The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
    Oct 19, 2023

    NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
    • (no location specified)
    Aug 27, 2023

    NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • (no location specified)
    May 23, 2023

    NSCLC Trial in China (HSK40118)

    Recruiting
    • NSCLC
    • Beijing, Beijing, China
    • +11 more
    Sep 18, 2023

    Non-squamous NSCLC Trial (biological, drug, dietary supplement)

    Not yet recruiting
    • Non-squamous NSCLC
    • Pembrolizumab
    • +7 more
    • (no location specified)
    Feb 20, 2023

    EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

    Recruiting
    • EGFR Exon 20 Mutation
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 12, 2022

    EGF-R Positive NSCLC, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion Trial in Bogotá (Stereotactic Body Radiation Therapy

    Not yet recruiting
    • EGF-R Positive Non-Small Cell Lung Cancer
    • +4 more
    • Stereotactic Body Radiation Therapy SBRT
    • Bogotá, Colombia
      CTIC - Centro de Tratamiento e Investigación Sobre Cáncer Luis C
    Aug 16, 2023

    Learn About Tests Looking forGene Mutation in Lung Cancer in

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • No Intervention
    • Beijing, China
      Department of Pathology, National Cancer Center/National Clinica
    Feb 24, 2023

    Brain Metastases, Radiotherapy, EGFR Activating Mutation Trial in Guangdong (brain radiotherapy, Almonertinib)

    Recruiting
    • Brain Metastases
    • +2 more
    • Guangdong, Guangzhou, China
      Sun-Yat-Sen university
    Mar 13, 2023

    NSCLC With Mutation in Epidermal Growth Factor Receptor Trial in Kunming (Combined therapy of anlotinib and aumolertinib)

    Recruiting
    • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
    • Combined therapy of anlotinib and aumolertinib
    • Kunming, Yunnan, China
      First Affiliated Hospital of Kunming University
    Oct 22, 2023

    A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib

    Recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • +4 more
      • Guangzhou, Guangdong, China
        Cancer Center, Sun Yat-sen University
      Oct 25, 2022

      NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

      Terminated
      • Carcinoma, Non-Small-Cell Lung
      • Maastricht, Limburg, Netherlands
      • +4 more
      Nov 7, 2022

      Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor Trial in Jerusalem (concomitant TTFields treatment

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • +2 more
      • concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
      • concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
      • Jerusalem, Israel
        Shaare Zedek Medical Center
      Jan 22, 2023

      NSCLC Trial in Shanghai (Furmonertinib 160mg, Furmonertinib 240mg)

      Recruiting
      • NSCLC
      • Furmonertinib 160mg
      • Furmonertinib 240mg
      • Shanghai, China
        Shanghai Chest hospital
      Jan 16, 2023

      Furmonertinib, EGFR-mutation, NSCLC Trial in Beijing (Furmonertinib)

      Recruiting
      • Furmonertinib
      • +3 more
      • Beijing, China
        Ethics Committee
      Jul 15, 2022

      NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • +2 more
      • Fairfax, Virginia
        NEXT Virginia
      Sep 18, 2023